Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

Here’s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peak

(Biotech Stocks Hitting 52-week highs on Jan. 8)

  • Innoviva Inc (NASDAQ: INVA)
  • Organogenesis Holdings Inc (NASDAQ: ORGO) (announced positive Nasdaq listing determination)
  • PDL BioPharma Inc (NASDAQ: PDLI)
  • Takeda Pharmaceutical Co Ltd (NYSE: TAK) (announced completion of acquisition of Shire)

Down In The Dumps

(Biotech Stocks Hitting 52-week lows on Jan. 8)

  • Avrobio Inc (NASDAQ: AVRO)
  • AxoGen, Inc Common Stock (NASDAQ: AXGN)
  • Diplomat Pharmacy Inc (NYSE: DPLO)
  • NuVasive, Inc. (NASDAQ: NUVA)
  • Viveve Medical Inc (NASDAQ: VIVE)

Stocks In Focus

BioMarin Revises Down FY18 Earnings Guidance

At the JPMorgan Health Care Conference, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updated guidance for 2018, with the overall revenue guidance largely unchanged at $1.47 billion to $1.53 billion. Kuvan net product revenue guidance was lowered from $440 million to $480 million to $430

... read more at: https://www.benzinga.com/general/biotech/19/01/12956194/the-daily-biotech-pulse-biomarin-trims-outlook-medicinova-enrolls-fir